Allogeneic and Autologous Cell Therapies Report 2022 (gate)

Allogeneic and Autologous Cell Therapies Report 2022Product types, manufacturing strategies and future trends across the industryThis full report by Informa Connect and Catalent reveals emerging trends in allogeneic and autologous cell therapy space.Contents

INTRODUCTION

In December 2021, Informa Connect and Catalent conducted a worldwide survey of cell therapy professionals to understand the emerging trends in both the allogeneic and autologous cell therapy space.Respondents were asked about their focus areas, product types and phases of their programs, in addition to their decision-making and the most significant challenges to their manufacturing goals.The full report reveals cell therapy manufacturing trends amid the rapid progression of cell therapy technologies.

KEY FINDINGS INCLUDE:

63% of cell therapy professionals are working on both autologous and allogeneic products

Supply chain bottlenecks are the most common hurdle that cell therapy professionals have experienced with their programs

Respondents gave valuable insights into next-generation innovative technologies they are most likely to adopt

About Catalent

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs.With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses.An experienced and innovative partner, it has a global network of dedicated, small- and large-scale clinical and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe.With integrated solutions for plasmid DNA, viral vectors and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.